share_log

Dow Falls 150 Points; Oracle Posts Downbeat Results

Dow Falls 150 Points; Oracle Posts Downbeat Results

道琼斯指数下跌150点;甲骨文发布令人失望的业绩
Benzinga ·  2024/12/10 22:49

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday.

今天上午美国股市涨跌互现,道琼斯指数周二下跌约150点。

Following the market opening Tuesday, the Dow traded down 0.36% to 44,242.81 while the NASDAQ rose 0.43% to 19,820.91. The S&P 500 also fell, dropping, 0.01% to 6,052.43.

周二开盘后,道琼斯指数下跌0.36%,至44,242.81点,而纳斯达克指数上涨0.43%,至19,820.91点。标准普尔500指数也下跌了0.01%,至6,052.43点。

Leading and Lagging Sectors
Communication services shares jumped by 2.3% on Tuesday.

领先和落后的行业
周二,通信服务股上涨了2.3%。

In trading on Tuesday, utilities shares fell by 1.1%.

在周二的交易中,公用事业股下跌了1.1%。

Top Headline

热门标题

Oracle Corporation (NYSE:ORCL) posted weaker-than-expected earnings and sales results for its second quarter on Monday.

甲骨文公司(纽约证券交易所代码:ORCL)周一公布的第二季度收益和销售业绩均低于预期。

The company reported second-quarter revenue of $14.06 billion, up 9% year-over-year. The revenue total missed a Street consensus estimate of $14.11 billion.

该公司报告第二季度收入为140.6亿美元,同比增长9%。总收入未达到华尔街共识估计的141.1亿美元。

Equities Trading UP

股票交易上涨

  • Chimerix, Inc. (NASDAQ:CMRX) shares shot up 172% to $2.36 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.
  • Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) got a boost, surging 112% to $2.6400 after the company announced the FDA has approved its supplemental new drug application for acetadote.
  • uniQure N.V. (NASDAQ:QURE) shares were also up, gaining 104% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.
  • Chimerix, Inc.(纳斯达克股票代码:CMRX)股价飙升了172%,至2.36美元,此前该公司宣布将向美国食品药品管理局提交用于复发性H3 K2700万突变弥漫性神经胶质瘤患者的多达维酮,以加速获得美国食品药品管理局的批准。
  • 坎伯兰制药公司(纳斯达克股票代码:CPIX)的股价上涨,在该公司宣布美国食品药品管理局已批准其醋酸盐补充新药申请后,该公司股价飙升了112%,至2.6400美元。
  • UniQure N.V.(纳斯达克股票代码:QURE)股价也上涨了104%,至15.00美元,此前该公司宣布与美国食品药品管理局就AMT-130加速路径的关键要素达成协议。

Equities Trading DOWN

股票交易下跌

  • CervoMed Inc. (NASDAQ:CRVO) shares dropped 75% to $2.54 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.
  • Shares of Biora Therapeutics, Inc. (NASDAQ:BIOR) were down 44% to $0.7499.
  • MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) was down, falling 41% to $1.65. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.
  • CervoMed Inc.(纳斯达克股票代码:CRVO)股价下跌75%,至2.54美元,此前该公司宣布其Neflamapimod的第20期试验未能达到其治疗痴呆症的关键终点。
  • Biora Therapeutics, Inc.(纳斯达克股票代码:BIOR)的股价下跌44%,至0.7499美元。
  • MediRom Healthcare Technologies Inc.(纳斯达克股票代码:MRM)下跌41%,至1.65美元。Medirom Healthcare将其500万美元的286万股美国存托股票的公开发行定价为每股ADS1.75美元。

Commodities
In commodity news, oil traded up 0.1% to $68.40 while gold traded up 1% at $2,712.20.

大宗商品
在大宗商品新闻方面,石油价格上涨0.1%,至68.40美元,而黄金上涨1%,至2712.20美元。

Silver traded up 0.4% to $32.750 on Tuesday, while copper fell 0.6% to $4.2500.

周二,白银上涨0.4%,至32.750美元,而铜价下跌0.6%,至4.2500美元。

Euro zone

欧元区

European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.6%.

今天欧洲股市大多走低。欧元区斯托克600指数下跌0.2%,德国DAX指数上涨0.2%,法国CAC 40指数下跌0.6%。西班牙的IBEX 35指数下跌0.1%,而伦敦富时100指数下跌0.6%。

Asia Pacific Markets

亚太市场

Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.

周一亚洲市场收盘涨跌互现,日本日经225指数上涨0.18%,香港恒生指数上涨2.76%,中国上证综合指数下跌0.05%,印度BSE Sensex下跌0.25%。

Economics

经济学

U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.

美国非农商业部门的劳动生产率在第三季度增长了2.2%,与初步数据一致。

Now Read This:

现在阅读这篇文章:

  • Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
  • 亚马逊将上涨约15%?以下是周二分析师的十大预测
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发